Cempra to develop antibiotic solithromycin for pediatric use and biodefense
The fourth generation macrolide antibiotic is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults. Cempra chief executive officer Prabhavathi Fernandes said BARDA has recognized
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.